Symbols

OCGN

Ocugen·NASDAQ

--(--)

OCGN fundamentals

OCGN Q4 2025 Earnings

Ocugen (OCGN) released its earnings on Mar 4, 2026: revenue was -193.00K (YoY -125.26%), missed estimates; EPS was -0.06 (YoY -20.00%), missed estimates.

Revenue / YoY

-193.00K

-125.26%

EPS / YoY

-0.06

-20.00%

Report date

Mar 4, 2026

OCGN Earnings Call Summary for Q4,2025

OCU400 Milestone: Phase III enrollment complete; Q1 2027 top-line data on 140 patients targeting 98% of RP patients.
OCU410ST Progress: 50% lesion reduction in Phase II/III interim; easy endpoint shows early photoreceptor preservation.
OCU410 Dry AMD: 46% lesion growth reduction vs. control; Phase III planned for 2026.
Financial Strength: $22.5M raise + $30M warrant potential extend cash runway to Q2 2027.
Strategic Focus: Gene therapy pipeline advancing with 3 BLA filings expected by 2027.

Earnings

EPS

Revenue

Revenue & Expenses

OCGN has released its 2025 Q4 earnings report, with revenue of -193.00K, reflecting a YoY change of -125.26%, and net profit of -17.71M, showing a YoY change of -27.56%. The Sankey diagram below clearly presents OCGN's revenue sources and cost distribution.

Key Indicators

Ocugen (OCGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ocugen (OCGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ocugen (OCGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ocugen (OCGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown